Quarterly report pursuant to Section 13 or 15(d)

Segment Information

v3.20.1
Segment Information
6 Months Ended
Feb. 29, 2020
Segment Reporting [Abstract]  
Segment Information

16.        Segment Information

 

The Company’s operations involve the development and usage, including licensing, of its proprietary nutrient infusion Technology. Lexaria is centrally managed and its chief operating decision makers, being the President and the CEO, use the consolidated and other financial information supplemented by revenue information by category of alternative health consumer products and technology licensing to make operational decisions and to assess the performance of the Company. The Company has identified two reportable segments: Intellectual Property Licensing and Consumer Products. Licensing revenues are significantly concentrated on one licensee.

 

 

 

IP Licensing

 

 

Consumer Products

 

 

Corporate

 

 

Consolidated Total

 

   

$

   

$

   

$

   

$

 

External revenue

 

 

69,750

 

 

 

99,631

 

 

 

 

 

 

169,381

 

CoGS

 

 

 

 

 

(65,959 )

 

 

 

 

 

(65,959 )

Operating expenses

 

 

(300,034 )

 

 

(293,487 )

 

 

(1,432,156 )

 

 

(2,025,677 )

Segment loss

 

 

(230,284 )

 

 

(259,815 )

 

 

(1,432,156 )

 

 

(1,922,255 )

Total assets

 

 

694,684

 

 

 

124,412

 

 

 

1,167,130

 

 

 

1,986,226